Clinical Trials
1.0k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (685 trials with phase data)• Click on a phase to view related trials
Metastatic Lymph Node Distribution in the Ileum Mesentery of Cecal and Proximal Ascending Colon Cancer
- Conditions
- Colon Cancer
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 406
- Registration Number
- NCT07149623
Surgery Benefits Takayasu Arteritis With Stenosis in the Descending Aorta
- Conditions
- Takayasu Arteritis
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT07149805
Health Belief Model-Based Survey on Breast Self-Examination Awareness and Practice Among Community-Dwelling Middle-Aged and Older Women
- Conditions
- Breast NeoplasmsBreast Self-ExaminationCancer ScreeningHealth Belief Model
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 3000
- Registration Number
- NCT07149636
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, China
A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT07149818
Robotic Versus Open Surgery Following Neoadjuvant Therapy in Pancreatic Cancer: Evaluation of Safety and Oncologic Outcomes
- Conditions
- Pancreatic CancerNeoadjuvant TherapyRobotic Surgery
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT07147374
- Locations
- 🇨🇳
Department of General Surgery, Peking Union Medical College Hospital (PUMCH), Beijing, Beijing Municipality, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 201
- Next
News
Dual-Targeting Radiopharmaceutical Shows 89% Response Rate in Advanced Cancer Trial
A novel dual-targeting radiopharmaceutical therapy targeting two cancer cell markers simultaneously demonstrated safety and efficacy in a first-in-human trial with nine advanced adenocarcinoma patients.
SCG101 Shows Dual Antiviral and Antitumor Effects in HBV-Related Liver Cancer Trial
SCG Cell Therapy's Phase 1 trial of SCG101, an autologous HBV-specific TCR-T cell therapy, demonstrated sustained clearance of hepatitis B surface antigen in 94% of heavily pre-treated HBV-related liver cancer patients.
Phase 3 Trial Shows High-Dose Radiotherapy Significantly Improves Survival in Limited-Stage Small Cell Lung Cancer
A phase 3 trial demonstrated that high-dose (54 Gy) hyper-fractionated twice-daily radiotherapy significantly improved overall survival to 60.7 months compared with 39.5 months for standard-dose (45 Gy) in limited-stage small cell lung cancer patients.
Ripretinib Demonstrates Efficacy as Neoadjuvant Therapy for GIST in First Case Report
A 57-year-old female with a large gastrointestinal stromal tumor (GIST) achieved successful R0 resection after neoadjuvant ripretinib therapy, marking the first reported case of ripretinib use in this setting.
Tislelizumab Plus Chemotherapy Shows Promise in Esophageal Cancer Treatment
A Phase 2 study reveals that perioperative tislelizumab combined with neoadjuvant chemotherapy yields a 44% pathological complete response (pCR) rate in resectable ESCC.
Pembrolizumab Plus Chemoradiotherapy Improves PFS in East Asian Cervical Cancer Patients
In East Asian patients with high-risk, locally advanced cervical cancer, pembrolizumab plus concurrent chemoradiotherapy (CCRT) significantly improved progression-free survival (PFS).